Tempus AI, Inc. (NASDAQ:TEM) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Tempus AI, Inc. (NASDAQ:TEM) have received an average recommendation of “Moderate Buy” from the twelve analysts that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $56.36.

Several brokerages recently issued reports on TEM. Guggenheim began coverage on Tempus AI in a research note on Monday, December 9th. They set a “buy” rating and a $74.00 price target on the stock. Bank of America boosted their price target on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Loop Capital lowered their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Piper Sandler restated a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Finally, Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and boosted their price target for the company from $45.00 to $65.00 in a research note on Monday, November 11th.

Tempus AI Stock Down 6.3 %

Shares of NASDAQ:TEM opened at $51.40 on Friday. The stock’s 50-day moving average is $44.36 and its 200-day moving average is $47.59. Tempus AI has a 52-week low of $22.89 and a 52-week high of $79.49. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Insiders Place Their Bets

In other Tempus AI news, major shareholder Bradley A. Keywell sold 395,800 shares of Tempus AI stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the transaction, the insider now directly owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. The trade was a 2.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Eric P. Lefkofsky sold 85,788 shares of the stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $53.39, for a total value of $4,580,221.32. Following the completion of the sale, the chief executive officer now owns 5,771,787 shares of the company’s stock, valued at $308,155,707.93. This trade represents a 1.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,862,758 shares of company stock valued at $79,585,675.

Institutional Trading of Tempus AI

A number of large investors have recently bought and sold shares of TEM. Kovitz Investment Group Partners LLC acquired a new stake in Tempus AI in the 3rd quarter valued at approximately $1,367,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Tempus AI by 1,591.2% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after purchasing an additional 1,145,698 shares during the last quarter. Captrust Financial Advisors acquired a new stake in shares of Tempus AI in the third quarter valued at approximately $2,726,000. Sigma Planning Corp bought a new stake in shares of Tempus AI in the third quarter worth $1,323,000. Finally, Dakota Wealth Management acquired a new position in Tempus AI during the third quarter worth $1,185,000. 24.22% of the stock is owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.